Scopio Labs, a provider of full-field morphology based in Tel Aviv, has launched its FDA-cleared and CE-approved Full-Field Peripheral Blood Smear (FF-PBS) application on the X100 platform. The application is designed to enable earlier detection, diagnosis, and treatment for improved patient outcomes.

According to the company, the FF-PBS application is the first end-to-end digital blood smear application that offers full-field imaging and an AI-powered decision support system with remote capabilities. The application was created to streamline workflows for laboratories and clinicians while optimizing the blood smear analysis process.  

Scopio’s imaging platform uses computational photography to provide images of vast numbers of cells, giving laboratory practitioners a full-field view of all regions of interest on the slide at 100X magnification, including the feathered edge. This allows laboratory teams and hematopathologists to see the scan in full context or to zoom in to the smallest details. 

The FF-PBS application features adaptive monolayer identification for optimal analysis, supporting both short and long smears, white blood cell detection, preclassification and quantification into sixteen classes, red blood cell morphology evaluation from 1,000 fields of view, and automated platelet location and pre-estimation. The results of every assessment, including annotations and flagged abnormalities, are all documented in a standardized digital report that is easily shared across the continuum of care.

According to the International Journal of Hematology, using Scopio’s full-field peripheral blood smear (FF-PBS) application reduces turnaround time for sample reviews by 60%, which optimizes laboratory workflows and the ability to deliver results for improved patient care.  

“Surprisingly, the healthcare industry still depends on inefficient solutions for blood smear analysis, having to choose between manual review on the microscope or solutions that only offer a partial view to base diagnoses on,” says Itai Hayut, CEO of Scopio Labs. “Our digital approach overcomes the tradeoff between resolution and field of view, allowing labs to analyze all relevant regions on a blood scan at an unprecedented resolution while maintaining full-field context – without necessitating manual counting. This gives labs and clinicians a complete picture for each case, which, combined with our AI-driven decision support system, ensures they can work more efficiently and never have to go back for a manual review of the sample.” 

Scopio’s browser-based remote solution enables offsite colleagues, hematopathologists, and clinicians to review, collaborate, or consult securely. Regardless of location, clinicians have the same access to the full-field images and insights as anyone in the laboratory, along with complete annotations for traceability and the ability to view any area of interest on a scan at 100X in real-time. This allows for second-opinion referrals to happen instantly and for treatment to begin earlier. 

Scopio’s technology has already been implemented at hospitals and laboratories in the United States, Europe, and Israel.

For more information, visit Scopio Labs.

Featured Image: According to the company, Scopio Labs’ high-resolution imaging with an AI-based decision support system yields a 60% more efficient workflow, while providing remote capabilities and delivering more consistent results. Photo: Scopio Labs